
## Nina F Schor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4223788/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Apoptosis in the absence of caspase 3. Oncogene, 2001, 20, 6570-6578.	2.6	205
2	Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis. FEBS Letters, 2000, 477, 1-7.	1.3	162
3	What the halted phase III γâ€secretase inhibitor trial may (or may not) be telling us. Annals of Neurology, 2011, 69, 237-239.	2.8	89
4	Direct Evidence for Antioxidant Effect of Bcl-2 in PC12 Rat Pheochromocytoma Cells. Archives of Biochemistry and Biophysics, 1997, 344, 413-423.	1.4	84
5	The Decanal Divide: Women in Decanal Roles at U.S. Medical Schools. Academic Medicine, 2018, 93, 237-240.	0.8	68
6	Implementation of a Longitudinal Mentored Scholarly Project: An Approach at Two Medical Schools. Academic Medicine, 2010, 85, 429-437.	0.8	67
7	The "neuro―of neuroblastoma: <scp>N</scp> euroblastoma as a neurodevelopmental disorder. Annals of Neurology, 2016, 80, 13-23.	2.8	54
8	The Endoplasmic Reticulum Stress Response Factor CHOP-10 Protects against Hypoxia-induced Neuronal Death. Journal of Biological Chemistry, 2010, 285, 21329-21340.	1.6	52
9	Bobble—head doll syndrome and drop attacks in a child with a cystic choroid plexus papilloma of the third ventricle. Journal of Neurosurgery, 1995, 83, 729-732.	0.9	44
10	Presenilin-1-Dependent Transcriptome Changes. Journal of Neuroscience, 2005, 25, 1571-1578.	1.7	42
11	Expression and p75 neurotrophin receptor dependence of cholesterol synthetic enzymes in adult mouse brain. Neurobiology of Aging, 2007, 28, 1522-1531.	1.5	41
12	Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology, 2010, 65, 1047-1056.	1.1	34
13	Glutamate-induced cytotoxicity in PC12 pheochromocytoma cells: role of oxidation of phospholipids, glutathione and protein sulfhydryls revealed by bcl-2 transfection. Molecular Brain Research, 1998, 60, 270-281.	2.5	31
14	Pharmacologic Management of High-Risk Neuroblastoma in Children. Paediatric Drugs, 2011, 13, 245-255.	1.3	31
15	The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell, 2005, 4, 187-196.	3.0	28
16	Effects of pH on the Cytotoxicity of Sodium Trioxodinitrate (Angeli's Salt). Journal of Medicinal Chemistry, 2004, 47, 210-217.	2.9	27
17	Loss of c/EBP-β activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons. Molecular and Cellular Neurosciences, 2008, 38, 125-137.	1.0	27
18	Formation of Nitroxyl and Hydroxyl Radical in Solutions of Sodium Trioxodinitrate. Journal of Biological Chemistry, 2003, 278, 42761-42768.	1.6	25

#	Article	IF	CITATIONS
19	Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Research, 2006, 1093, 71-82.	1.1	25
20	PRMT1 promotes neuroblastoma cell survival through ATF5. Oncogenesis, 2020, 9, 50.	2.1	24
21	Anticipatory Guidance as a Principle of Faculty Development: Managing Transition and Change. Academic Medicine, 2011, 86, 1235-1240.	0.8	23
22	P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of Disease, 2005, 20, 969-985.	2.1	22
23	Pharmacotherapy for adults with tumors of the central nervous system. , 2009, 121, 253-264.		22
24	In-tube transfection improves the efficiency of gene transfer in primary neuronal cultures. Journal of Neuroscience Methods, 2009, 177, 348-354.	1.3	22
25	Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma. Oncotarget, 2016, 7, 63629-63639.	0.8	19
26	Prevention of catecholaminergic oxidative toxicity by 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl and its recycling complex with polynitroxylated albumin, TEMPOL/PNA. Brain Research, 2004, 1012, 13-21.	1.1	17
27	Transcriptome Differences Between the Frontal Cortex and Hippocampus of Wild-Type and Humanized Presenilin-1 Transgenic Mice. American Journal of Geriatric Psychiatry, 2005, 13, 1041-1051.	0.6	16
28	New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. , 2009, 122, 44-55.		15
29	Kidins220/ARMS depletion is associated with the neural-to Schwann-like transition in a human neuroblastoma cell line model. Experimental Cell Research, 2013, 319, 660-669.	1.2	15
30	Adult neurology training during child neurology residency. Neurology, 2012, 79, 815-818.	1.5	13
31	The supportive academic environment: ingredients for success. Pediatric Neurology, 2003, 29, 370-373.	1.0	12
32	The child is father to the man: Developmental roles for proteins of importance for neurodegenerative disease. Annals of Neurology, 2010, 67, 151-158.	2.8	12
33	Why our patients (and we) need basic science research. Neurology, 2013, 80, 2070-2075.	1.5	12
34	Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary. Molecular Therapy, 2021, 29, 3332-3344.	3.7	12
35	p75NTR: an enhancer of fenretinide toxicity in neuroblastoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 777-787.	1.1	10
36	Kidins220/ARMS is expressed in neuroblastoma tumors and stabilizes neurotrophic signaling in a human neuroblastoma cell line. Pediatric Research, 2013, 74, 517-524.	1.1	10

#	Article	IF	CITATIONS
37	Depletion of glutathione by the radioprotective agent S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR2721). Biochemical Pharmacology, 1988, 37, 562-563.	2.0	9
38	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	1.1	9
39	Treatment with propofol: The new status quo for status epilepticus?. Neurology, 2005, 65, 506-507.	1.5	8
40	Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. Cancer Chemotherapy and Pharmacology, 2008, 62, 699-706.	1.1	8
41	Role of Tyrosine Phosphorylation in The Antioxidant Effects of The P75 Neurotrophin Receptor. Oxidative Medicine and Cellular Longevity, 2009, 2, 238-246.	1.9	8
42	Necdin and TrkA contribute to modulation by p75NTR of resistance to oxidant stress. Experimental Cell Research, 2009, 315, 3532-3542.	1.2	8
43	Necdin and Neurotrophin Receptors: Interactors of Relevance for Neuronal Resistance to Oxidant Stress. Pediatric Research, 2011, 69, 279-284.	1.1	7
44	Neurodevelopmental Clues to Neurodegeneration. Pediatric Neurology, 2021, 123, 67-76.	1.0	7
45	Chopper Is Prodeath Regardless of the Effect of p75ICD on Sensitivity to Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2011, 2011, 1-8.	1.9	6
46	p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 271-279.	1.1	6
47	EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers. Journal of Cancer Research & Therapy, 2016, 4, 11-18.	0.1	6
48	p75NTR enhances PC12 cell tumor growth by a non-receptor mechanism involving downregulation of cyclin D2. Experimental Cell Research, 2006, 312, 3287-3297.	1.2	5
49	Life at the interface: Adults with "pediatric―disorders of the nervous system. Annals of Neurology, 2013, 74, n/a-n/a.	2.8	5
50	Using Chemistry to Target Neuroblastoma. ACS Chemical Neuroscience, 2017, 8, 2118-2123.	1.7	5
51	Aiming at Neuroblastoma and Hitting Other Worthy Targets. Journal of Child Neurology, 2013, 28, 768-773.	0.7	3
52	Pursuit and achievement of leadership: A view from the top. Annals of Neurology, 2014, 76, 784-788.	2.8	3
53	Induction of Expression of p75 Neurotrophin Receptor Intracellular Domain Does Not Induce Expression or Enhance Activity of Mitochondrial Complex II. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-5.	1.9	3
54	Methylation of the phosphataseâ€transcription activator EYA1 by protein arginine methyltransferase 1: mechanistic, functional, and structural studies. FASEB Journal, 2017, 31, 2327-2339.	0.2	3

#	Article	IF	CITATIONS
55	NINDS launches network to develop treatments for ultra-rare neurological diseases. Nature Biotechnology, 2021, 39, 1497-1499.	9.4	3
56	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . Journal of Medicinal Chemistry, 2022, 65, 6039-6055.	2.9	3
57	Pediatric Residency Preceding Child Neurology Training. Seminars in Pediatric Neurology, 2011, 18, 131-132.	1.0	2
58	Personal health information in verse. Neurology, 2013, 81, e123.	1.5	2
59	Comment: Autonomy vs beneficence. Neurology, 2014, 83, 1370-1370.	1.5	2
60	Cell Line-Dependent Variability of Coordinate Expression of p75NTR and CRABP1 and Modulation of Effects of Fenretinide on Neuroblastoma Cells. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-8.	1.9	2
61	Women in medical school leadership positions: Implications for research. Annals of Neurology, 2019, 85, 789-792.	2.8	2
62	Saving neurology. Neurology, 2019, 93, 989-990.	1.5	2
63	Diversifying Child Neurology: Developing a Workforce That Reflects the Patients and Families for Whom We Care. Pediatric Neurology, 2020, 112, 22-24.	1.0	2
64	The NINDS 2021–2026 Strategic Plan: Partnership and cross-cutting principles. Cell, 2022, 185, 1445-1448.	13.5	2
65	Child neurology: A trilogy. Neurology, 2006, 66, 613-613.	1.5	1
66	Brain Mets: A poem in three voices. Neurology, 2006, 66, 457-457.	1.5	1
67	Pediatric neurohospitalists. Neurology, 2013, 80, 880-881.	1.5	1
68	Child neurologists and neurodevelopmental disabilities physicians. Neurology, 2016, 87, 1318-1319.	1.5	1
69	The Electronic Medical Record and Computerized Physician Order Entry: Challenges and Opportunities for Pediatrics. Journal of Pediatrics, 2016, 176, 5-6.	0.9	1
70	Autism today. Neurology, 2017, 88, 1303-1304.	1.5	1
71	A Life at the Interface: The 2017 Hower Award Lecture. Pediatric Neurology, 2018, 80, 3-7.	1.0	1
72	Programmatic Foci of Women in Academic Leadership Positions at Historically Black Colleges and Universities: Intersectionality and Institutional Mission. Journal of Women in Educational Leadership, 0, , .	0.0	1

#	Article	IF	CITATIONS
73	Career equity in medicine. Nature Medicine, 2021, 27, 746-746.	15.2	1
74	Developmental Arrest. Neurology, 2008, 71, 1038-1038.	1.5	0
75	Crossroads: Two Points of View: RESIDENT WORK HOURS: ISOLATING ONE LEDGER COLUMN AND MISSING THE POINT. Neurology, 2008, 71, 374-374.	1.5	Ο
76	Reflections for January. Neurology, 2010, 74, 179-179.	1.5	0
77	Robert J. Joynt, MD, PhD. Journal of Child Neurology, 2012, 27, 1077-1078.	0.7	0
78	Introductory address for the John Howland Award recipient, Elizabeth R. McAnarney, MD. Pediatric Research, 2013, 74, 473-474.	1.1	0
79	Chance juxtapositions and (un)biased methods in science. Neurology, 2017, 89, 218-219.	1.5	0
80	Current Pharmacotherapy for Neuroblastoma. , 2019, , 203-211.		0
81	Neurology Year-in-review—Pediatric Neurology. US Neurology, 2015, 11, 106.	0.2	0